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Review
The Hammer and the Dance of Cell
Cycle Control
Andreas Panagopoulos1 and Matthias Altmeyer1,*
Cell cycle checkpoints secure ordered progression from one cell cycle phase
to the next. They are important to signal cell stress and DNA lesions and to
stop cell cycle progression when severe problems occur. Recent work suggests,
however, that the cell cycle control machinery responds in more subtle and
sophisticated ways when cells are faced with naturally occurring challenges,
such as replication impediments associated with endogenous replication stress.
Instead of following a stop and go approach, cells use fine-tuned deceleration
and brake release mechanisms under the control of ataxia telangiectasia and
Rad3-related protein kinase (ATR) and checkpoint kinase 1 (CHK1) to more flex-
ibly adapt their cell cycle program to changing conditions.We highlight emerging
examples of such intrinsic cell cycle checkpoint regulation and discuss their
physiological and clinical relevance.
From Stop and Go Cell Cycle Decisions to a Continuum of Deceleration and
Brake Release Mechanisms
Cell cycle checkpoints (see Glossary) are control mechanisms that ensure proper and ordered
progression of cells through the cell cycle [1]. Genome integrity maintenance is among the key
tasks of cell cycle checkpoint control, and DNA damage checkpoints have thus evolved to trigger
cell cycle arrest in response to genomic lesions and allow time for repair [2]. The cell cycle check-
point model, in agreement with the general meaning of the term checkpoint, implies certain criteria,
which have to be met by a cell to continue its progression through the cell cycle (the ‘go’ decision)
and which, if they are not fulfilled, lead to transient or permanent cell cycle arrest (the ‘stop’
decision). Among the major cell cycle checkpoints are the G1/S checkpoint, the G2/M checkpoint,
and the spindle checkpoint in mitosis. By analogy to ‘the hammer and the dance’ metaphor
introduced early in 2020 by Tomas Pueyo to emphasize the importance of acting quickly and force-
fully to contain the global health threat posed by SARS-CoV-2 and later ease and adapt the mea-
sures to continually manage and control COVID-19 (‘Coronavirus: the hammer and the dance’,
published online March 19, 2020; https://medium.com/@tomaspueyo/coronavirus-the-hammer-
and-the-dance-be9337092b56), we can consider full checkpoint activation to halt cell cycle pro-
gression as ‘the hammer’, which can be an effective means to minimize further damage in the
face of severe threats to genome integrity. However, rather than relying exclusively on binary
stop and go decisions, a picture is starting to emerge in which the cell cycle control machinery
uses fine-tuned brakes and brake releasemechanisms [3], thereby temporarily decelerating certain
processes while continuing others, to globally balance genome surveillancewith cell cycle progres-
sion (‘the dance’). Thus, cell cycle arrest as an extreme measure seems reserved for severe events
that threaten genome integrity and cell survival, while more moderate and adaptable measures are
commonly used by cells to deal with controllable genomic lesions and replication intermediates
associated with endogenous replication stress in a more flexible and context-specific manner.
In this review, we aim to provide a synthesis of recent findings that shed new light on cell cycle
checkpoint functions during unperturbed cell proliferation and in the presence of endogenous
Highlights
Shutdown of cell cycle progression by
checkpoint activation is the exception
rather than the norm when cells face
physiological levels of replication stress.
In response to endogenous replication
stress, cells use tunable deceleration
and brake release mechanisms under
the control of the ATRandCHK1kinases
for timely completion of DNA duplication.
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and mild forms of exogenous replication stress, with a particular focus on replication check-
point signaling in mammalian cells. We discuss sources of endogenous replication stress (i.e.,
replication challenges occurring during normal cell cycle progression and, in an exacerbated
manner, during cellular transformation and cancer development). Rather than providing an elab-
orate characterization of the many specialized factors that are involved in resolving these prob-
lems, which have been summarized more comprehensively elsewhere [4–6], we discuss how
the replication program itself is buffered against such naturally occurring challenges and how rep-
lication checkpoint maintenance enables S-phase completion while at the same time allowing
cells to resolve naturally occurring replication impediments.
We then focus on the major replication checkpoint kinases ATR and CHK1 and their functions
during unperturbed replication and in response to endogenous replication stress. We introduce
the emerging notion that not only the type and severity of a replication problem determine check-
point decisions, but that the cellular response is also determined by how long a replication prob-
lem persists. Along these lines, we elucidate how low levels of endogenous replication stress are
important to maintain intrinsic checkpoint functions and are thus beneficial for genome integrity,
while persistent high levels of replication stress can lead to checkpoint adaptation and cell
cycle transitions with unresolved and potentially harmful genomic lesions.
Finally, we put the concept of tunable cell cycle checkpoint control into context with currently on-
going attempts to target cell cycle checkpoint kinases therapeutically. The new insights into the
regulation and the function of ATR and CHK1 during normal cell cycle progression and to deal
with naturally occurring endogenous replication stress (as it can be found in many cancer cells)
have direct implications for the targeted use of small molecule inhibitors against checkpoint ki-
nases in cancer therapy. We discuss these implications and provide an outlook on how the
changing cell cycle paradigm from stop and go checkpoint control to fine-tuned brake and
brake release regulation may help to better understand and treat human disease.
Cell Cycle Control in the Face of Genome Duplication under Stress
Genome integrity maintenance is of great importance for cell survival and homeostasis. To pre-
serve genome integrity and coordinate genome maintenance functions with cell cycle progres-
sion, cells use an elaborate network of intertwined surveillance pathways that coordinate cell
cycle checkpoint control. Due to their important genome maintenance functions, deregulation
of these signaling pathways contributes to cellular transformation, cancer, and aging. When
cells experience DNA lesions, they activate the DNA damage response (DDR), which is critical
for sensing, signaling, and repairing the damage [7,8]. The DDR comprises a large network of
proteins, which recognize different types of DNA lesions and coordinate their efficient repair. As
DDR functions involve the activation of DNA damage checkpoints to slow or stop cell cycle
progression, timely termination of the DDR is important for cells to resume cell cycle progression
once the damage is repaired. Many lesions, which challenge genome integrity, occur during DNA
replication in the form of replication intermediates and byproducts of physiological DNA transac-
tions. As such, they blur conventional definitions of DNA damage and have started to redefine cell
cycle checkpoints from binary stop and go switches towards dynamic brakes and brake release
mechanisms.
Sources of Replication Stress
The sources of replication stress are manifold and can hinder replication fork progression either
locally or genome wide, with implications for genome integrity maintenance and associated pa-
thologies [9,10]. The availability of building blocks for DNA synthesis is critical for replication
fork progression, and nucleotide shortage thus impairs fork speed and can lead to uncoupling
Glossary
Ataxia telangiectasia and Rad3-
related protein kinase (ATR): the
apical kinase responsible for the cellular
response to replication stress, essential
for cell proliferation and survival.
Cell cycle checkpoints: cellular
control mechanisms, which ensure
ordered progression through the cell
cycle. Proper cell cycle checkpoint
control is required to maintain genome
integrity and prevent cellular
transformation.
Checkpoint adaptation: the process
by which cells can resume cell cycle
progression despite the presence of
sustained, unresolved DNA damage.
Checkpoint kinase 1 (CHK1):
the main downstream effector kinase of
ATR; controls cell cycle progression,
origin firing, and the stabilization of
stalled replication forks.
Checkpoint maintenance:
the processes by which checkpoint
functions remain active during normal
cell proliferation to ensure ordered cell
cycle progression and safeguard
genome integrity maintenance.
Checkpoint termination: the process
by which checkpoint signaling is
switched off after successful repair of
DNA damage to allow the resumption of
cell cycle progression.
Chromosomal fragile sites:
genomic loci, which are inherently prone
to breakage (e.g., after exposure to
replication stress).
Cyclin-dependent kinase (CDK)
activity: CDKs are serine-threonine
protein kinases, which are activated by
cyclins in a cell cycle-dependent
manner. CDK activity promotes cell
cycle transitions and drives cell cycle
progression.
DNA damage response (DDR):
the cellular mechanisms responsible for
sensing DNA damage, signaling its
presence to the cell cycle control
machinery, and repairing the genome.
Dormant origins: licensed origins of
replication, which normally do not fire
during DNA replication. Dormant origins
serve as an important backup and are
used to rescue replication where
replication forks stall irreversibly.
Gene gating: the process by which
actively transcribed genes are transiently
positioned close to nuclear pores for the
productive coupling of transcription and
mRNA processing to mRNA export.
Intra-S-phase checkpoint: cell cycle
checkpoint mechanisms to slow the
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and exposure of single-stranded DNA (ssDNA) (Figure 1A). The rate-limiting step for the genera-
tion of deoxyribonucleotide triphosphates (dNTPs) is the conversion of nucleotide diphosphates
(NDPs) into deoxyribonucleotide diphosphates (dNDPs) by the enzyme ribonucleotide reductase
(RNR), and deregulation of RNR activity causes replication stress and genome instability [10].
Hydroxyurea (HU) is frequently used for RNR inhibition, but also oncogene activation can affect
dNTP synthesis and unbalance dNTP pools, thereby causing replication stress and promoting
mutagenesis [11]. To adapt to alterations in dNTP levels, cancer cells may sense an ensuing
change in redox potential and elevated reactive oxygen species (ROS) and actively slow
replication forks to prevent excessive damage [12].
Besides dNTP availability, replication fidelity is inherently linked to theDNA sequence. Repetitive se-
quences, which comprise large portions of the human genome, are potent sources of replication
stress and genome instability (Figure 1B). They canmisalign during DNA synthesis and are typically
associated with more compact and thus more difficult to replicate chromatin. Repeat expansions
cause several neurological and muscular diseases, and repetitive DNA sequences such as AT-rich
regions are associated with chromosomal fragile sites, breakpoints in the genome that contrib-
ute to genomic rearrangements and mutations in cancer [13,14]. Common fragile sites (CFSs) are
typically found in large transcribed domains with a low density of replication origins (Figure 1C),
which makes them particularly vulnerable to breakage [15,16]. Repetitive sequences and inverted
repeats are also prone to adopt secondary structures such as hairpins, cruciforms, and
G-quadruplexes in GC-rich areas (Figure 1D). These non-B DNA structures can stall replication
forks, cause DNA lesions, and are associated with translocation breakpoints in cancer [17].
Secondary structures have regulatory roles in transcription and transcription itself is an important
source of endogenous replication stress. Transcription–replication conflicts can arise from direct
collisions between the transcription and replication machineries (Figure 1E), which can occur
in both head-on and co-directional orientation. Such conflicts evoke the formation of
co-transcriptional R-loops (Figure 1F), structures that form when nascent RNAs hybridize back
to the template DNA and generate an RNA–DNA hybrid while displacing single-stranded non-
template DNA. Although R-loops have important physiological functions, they can also interfere
with replication fork progression and lead to genome instability (e.g., under conditions of
oncogene-induced replication stress) [18–20]. In particular, head-on collisions between the
replisome and the transcription machinery promote genome-destabilizing R-loops [21,22].
Interestingly, the ssDNA-binding protein RPA, an essential constitutive component of replication
forks, was recently shown to sense and suppress R-loops [23]. Furthermore, the replication and
repair factors BRCA1 and BRCA2 alleviate transcription–replication conflicts and play active roles
in R-loop regulation, and confer resistance to G-quadruplex-stabilizing compounds [24–26].
Replication fork progression can also be impaired by naturally occurring DNA lesions including bulky
DNA adducts and by covalent DNA crosslinks (Figure 1G) [9] as well as by DNA–protein crosslinks
(DPCs) ahead of the fork (Figure 1H) [27,28]. DPCs occur by linking nucleic acid-modifying enzymes
to DNA as trapped reaction intermediates and by nonenzymatic crosslinking of chromatin-
associated proteins, and they are emerging as an important source of genome instability [27,28].
The replisome-associated metalloprotease SPRTN (DVC1) plays a central role in DPC removal
and repair, and mutations in the SPRTN gene are associated with a premature aging phenotype
with early-onset hepatocellular carcinoma, known as Ruijs-Aalfs or SPARTAN syndrome [27–32].
Importantly, all of the structures mentioned in the preceding text can also result in topological
constraints on DNA replication (Figure 1I), and torsional stress (e.g., from DNA supercoiling)
can reduce fork speed and challenge fork stability [33–35]. We recently proposed that, analogous
DNA synthesis rate in response to DNA
damage (e.g., in the presence of DNA
DSBs).
Poly(ADP-ribose) polymerase
(PARP) inhibition: drug-induced block
of poly(ADP-ribose) synthesis by
PARPs, entailing genotoxic PARP
trapping.
Replication catastrophe: condition of
massive replication stress-associated
DNA damage during S phase; occurs
after the excessive formation of ssDNA
at stalled replication forks, which
exhausts the ssDNA-protecting RPA
pool.
Replication checkpoint: cell cycle
checkpoint mechanisms to sense
perturbations during DNA replication,
such as replication fork stalling, and to
coordinate fork remodeling and restart
with origin firing and S-phase
progression.
Replication origins: genomic loci from
which DNA replication initiates. Origins
are licensed for a new round of
replication in late mitosis and early G1.
Only approximately 10% of licensed
origins fire in a temporally and spatially
controlled manner during S-phase
progression, while the rest remain silent.
Replisome: the multiprotein complex
that, starting at replication origins,
unwinds the parental DNA and
synthesizes new DNA during the
process of genome duplication.
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Figure 1. Endogenous Sources of Replication Stress. Replication stress can be caused by various impediments that
interfere with the normal function of the replication machinery and impair replication fork progression. Sources of replication
stress include (A) nucleotide shortage, (B) repetitive DNA sequences, (C) chromosomal fragile sites, (D) DNA secondary
structures, (E) transcription–replication conflicts, (F) co-transcriptional R-loops, (G) replication fork-stalling DNA lesions,
and (H) DNA–protein crosslinks, as well as (I) topological constraints that affect replication fork progression. Oncogene
activation can exacerbate multiple causes of endogenous replication stress during cancer development.
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to gene gating in yeast (i.e., the direct coupling of transcription to mRNA export by localizing
transcription units close to the nuclear pore complex) [36], torsional stress arises when
co-transcriptional mRNA cleavage is deregulated and replisomes encounter transcription units
with unreleased nascent transcripts that localize close to the nuclear periphery [37]. This situation
renders cells highly dependent on replication stress signaling, a condition that can be relieved by
suppressed origin firing through cyclin-dependent kinase (CDK) inhibition [37]. Intriguingly, an
analogous situation of gene gating occurs during oncogenic MYC expression to enable efficient
transcription-coupled mRNA export [38]. It is thus tempting to speculate that, similar to
exhausted pre-mRNA cleavage and impaired mRNA release from gene bodies [37], oncogene
expression could also promote gene gating-associated replication stress and thereby enhance
genome instability in cancer.
The Replication Checkpoint as a Rheostat for Replication Control
With more sensitive tools to investigate replication intermediates and endogenous genomic le-
sions, the border between normally occurring replication structures and DNA damage has started
to blur. For instance, the intra-S-phase checkpoint has been defined as a mechanism to slow
or stop replication in response to DNA double-strand breaks (DSBs) [39]. By now we know that
replication forks undergo frequent fork reversal to form transient four-way junctions even in unper-
turbed conditions [6] and that the regressed arms of reversed replication forks resemble DSB
ends, which use canonical DDR factors [40]. A clean distinction between DNA damage-
induced and replication checkpoint signaling may therefore not always be possible. Moreover,
as demonstrated recently for interstrand crosslinks (ICLs), not only replication forks that directly
encounter lesions but also the majority of forks that are not directly affected by replication imped-
iments slow in an ATR-dependent manner [41]. Thus, at least for certain replication impediments,
local and global fork speed seem tightly connected by checkpoint kinase signaling.
ATR is the apical replication checkpoint kinase and together with its effector kinaseCHK1 coordinates
fork stabilization and fork speed, replication stress signaling, and origin firing. The latter is primarily
achieved by CHK1-mediated phosphorylation and subsequent degradation of the CDC25A
phosphatase, which reduces S-phase CDK activity by elevating inhibitory CDK phosphorylations.
Under conditions of acute replication stress, ATR–CHK1 signaling globally inhibits the firing of late rep-
lication origins, thereby limiting the number of active replication factories, while at the same time
allowing dormant origins in active factories to fire so that stalled replication forks nearby can be
recovered [42,43]. Replication obstacles can also be overcome by fork remodeling, repriming, and
post-replicative repair [10,44], and re-initiation of DNA synthesis past fork-stalling lesions, mediated
by the primase-polymerase PrimPol, is emerging as an important mechanism to promote genome
duplication under challenging conditions and to coordinate replication in space and time [45–47].
Overall, a picture of highly dynamic control of DNA replication and S-phase progression, buffered
against the different sources of replication stress and fork stalling lesions, arises in which not only
the type and severity of replication fork hindrance determine the outcome for genome integrity but
also, importantly, how long replication problems and fork stalling lesions persist (Figure 2).
Dynamic fork reversal is utilized when forks stall transiently, to remodel the fork structure into a
four-way junction thereby stabilizing the fork and buying time for the removal of the fork slowing
structure. Persistently stalled replication forks may use nucleolytic fork processing, repriming,
template switching, and translesion synthesis as part of the DNA damage tolerance pathway.
In more extreme cases, lasting replication blocks that cannot be bypassed can lead to fork col-
lapse and recombination-mediated repair and fork restart [48]. As cells continue their progression
through S phase, the time left to resolve replication stress-inducing lesions decreases and fewer
options remain. A key function of cell cycle checkpoint control in this context is to ensure that the
Trends in Biochemical Sciences
OPEN ACCESS
Trends in Biochemical Sciences, April 2021, Vol. 46, No. 4 305
cellular buffering is not exhausted too easily [49]. The ssDNA-binding protein RPA plays a critical
role in this buffering against endogenous and exogenous sources of replication stress, including
conditions of elevated ssDNA formation when leading and lagging strand DNA synthesis are
uncoupled [50]. Given the large excess of licensed replication origins, by tunable suppression
of origin firing the checkpoint kinases ensure that ssDNA formation is normally restricted and
that S-phase progression occurs within the limits of the replication capacity.
Intrinsic Replication Checkpoint Signaling
Early work investigated ATR and CHK1 functions mostly after induced DNA damage or severe
replication stress. ATR and CHK1 are essential kinases, however, and both are required for normal
S-phase progression (i.e., in absence of exogenous replication stress) [51–53]. The physiological
importance of this signaling axis is underscored by mutations in ATR that cause Seckel syndrome,
an autosomal recessive disorder characterized by intrauterine growth retardation, dwarfism,
microcephaly, craniofacial abnormalities, and intellectual disability [54]. During unperturbed
S-phase progression, ATR–CHK1 signaling continuously targets CDC25A for degradation
[55–57]. This restricts CDK activity and suppresses origin firing [58–61], and basal ATR–CHK1
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Figure 2. Fighting Against Time When Dealing with Replication Stress. Stalled replication forks trigger ataxia
telangiectasia and Rad3-related protein kinase (ATR) activation, which, via checkpoint kinase 1 (CHK1) phosphorylation
and its release from the chromatin, suppresses the firing of late origins, thus buying time to solve the problem. Dormant
origins in active replication clusters are allowed to fire, however, and can rescue stalled replication forks under conditions
of activated ATR–CHK1 signaling. Transiently stalled forks use fork reversal to remodel the fork structure into a four-way
junction and thereby stabilize it. Persistently stalled replication forks may use nucleolytic fork processing, repriming,
template switching, and translesion synthesis as part of the DNA damage tolerance pathway to overcome the problem.
Lasting replication blocks can lead to fork collapse and recombination-mediated repair and fork restart. Unless replication
is blocked completely (e.g., by global nucleotide depletion), S-phase progression does not necessarily stop in response to
replication stress. Rather, depending on the type and severity of the lesion and its relative abundance, replication fork
speed and origin firing are dynamically regulated while lesion removal, bypass, or damage repair occur simultaneously. As
a consequence, unresolvable problems and persistently stalled replication forks build up an increasing replication stress
level as cells continue to progress through S phase.
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replication to cell cycle progression and the timing of mitosis [62]. In other words, the replication
process itself activates a built-in tunable cell cycle brake.
As continuous activation of CHK1 is linked to CHK1 stability [63], this built-in cell cycle brake is
maintained as long as basal levels of CHK1 activity are being held up. Consistently, by the use of
a live-cell CDK reporter, it was recently shown that intrinsic replication checkpoint signaling results
in fluctuating changes in CDK2 activity during unperturbed S-phase progression, which constantly
adjusts DNA synthesis rates [64]. Downstream of CDK activity, a FOXM1-dependent transcription
program regulates the expression of mitotic genes, and the CDK1-mediated phosphorylation and
activation of the transcription factor FOXM1 is antagonized by ATR–CHK1 signaling until replication
is complete [65]. Intrinsic checkpoint signaling and endogenous replication stress thus link cell
cycle progression to the completion of genome duplication. Besides physical obstacles to replica-
tion fork progression as triggers of intrinsic checkpoint signaling, limiting dNTP supply at the onset
of S phase also causes checkpoint signaling to prevent overhasty replication [66]. Taken together,
these findings suggest that intrinsic replication checkpoint signaling acts as a rheostat for replica-
tion and cell cycle control, and that, rather than resembling a checkpoint in the classical sense of
the word, the ATR–CHK1 signaling axis can be viewed as a tunable brake, which protects prolifer-
ating cells from overheated DNA replication and from rushed or untimely cell cycle transitions.
The mechanisms that lead to the activation of ATR and CHK1 under unperturbed cell cycle pro-
gression remain incompletely understood. One of the players that seems to be involved is the
ATR activator ETAA1 [63,65,67]. ETAA1 localizes at replication forks and binds to RPA, ATR,
and ATRIP [68–70], suggesting that replication-associated ssDNA plays a role in intrinsic check-
point control. Indeed, RPA-covered ssDNA stimulates ETAA1-dependent ATR activation in vitro
[71]. ETAA1 also has mitotic functions [72,73], and additional sources of interphase ATR activa-
tion may exist. For instance, RNA polymerase II (RNAPII)-mediated transcription can induce ATR
signaling, and inactivation of the RNAPII CTD phosphatase PNUTS-PP1 greatly enhances ATR-
dependent phosphorylation [74]. Furthermore, it was recently shown that CHK1 activation under
unperturbed conditions can occur through proteolytic cleavage of its C-terminal autoinhibitory re-
gion by the SPRTN protease. This releases signaling-competent CHK1 and reinforces SPRTN re-
cruitment in a SPRTN–CHK1 cross-activation loop [75]. Downstream of CHK1 activation, its
autophosphorylation status is important for intrinsic checkpoint maintenance. Mutants of
CHK1, which are defective in autophosphorylation, show reduced stability due to enhanced
proteasomal degradation, and small molecule inhibitors targeting replication checkpoint signaling
disrupt intrinsic checkpoint maintenance [63]. While this sensitizes cells to acute replication
blocks, in absence of exogenous replication stress it leads to accelerated cell cycle progression
and replication-associated DNA lesions that are transmitted to daughter cells through cell divi-
sion. Such heritable genomic lesions affect cell cycle transitions in the next cell generation, sug-
gesting that intrinsic replication checkpoint signaling impacts cell cycle control far beyond S
phase [76–78]. Signaling from replication remnants after cell division, resembling part of the rep-
lication stress history, is integrated by cells with mitogen signaling and mitogen history to control
further proliferation [79–81]. Deregulated or impaired ATR–CHK1 signaling (e.g., by drug-induced
kinase inhibition) may therefore amplify endogenous replication stress levels across multiple cell
generations, with poorly understood implications for cell fate decisions and long-term cell survival.
CHK1 Regulation by Post-translational Modifications (PTMs) and Proteasomal
Degradation
PTMs are critical for the regulation of ATR–CHK1 signaling, both under conditions of acute repli-
cation stress and during unperturbed DNA replication. CHK1 is activated by the upstream ATR
kinase through phosphorylation at S317 and S345. The CHK1-interacting protein and coactivator
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Claspin, which is also phosphorylated by ATR, supports this step by promoting CHK1 recruitment
and facilitating its ATR-dependent phosphorylation [82]. Subsequently, CHK1 autophosphorylates
its residue S296, which causes its release from chromatin and promotes checkpoint signaling
[83,84]. Although several phosphatases are able to counteract CHK1 phosphorylation
(Figure 3A) [85–88], autophosphorylated CHK1 can be detected during unperturbed S-phase pro-
gression and is linked to the maintenance of CHK1 stability [63,75]. Multiple ubiquitin ligases, in-
cluding the SKP1-CUL1-F-box (SCF) complex, CUL4-DDB1, and HUWE1 [89–93] can target
CHK1 for proteasomal degradation, whereas the deubiquitinases USP1, USP3, USP7, and
Ataxin-3 [94–97] were shown to antagonize CHK1 ubiquitylation and degradation (Figure 3B).
Preventing unscheduled CHK1 inactivation and degradation during normal cell proliferation is crit-
ical for what we refer to as intrinsic checkpoint maintenance (Figure 4A). Under such conditions of
mild endogenous replication stress, keeping CDK activity in check by a tunable CHK1-dependent
cell cycle brake is important to maintain a sufficient buffering capacity and to avoid premature cell
cycle transitions. After full checkpoint activation by high levels of replication stress or acute DNA
damage, however, the main risk shifts towards excessive and prolonged checkpoint activation
and an inability to resume cell cycle progression. Checkpoint signaling therefore needs to be ter-
minated once replication stress is back under control and DNA lesions have been repaired. Such
checkpoint termination is mediated by the inactivation and proteolytic degradation of CHK1
and of its positive regulator Claspin [98–101], indicating that, while CHK1 inactivation and degra-
dation are dangerous for cells during normal replication and mild levels of replication stress, the
samemechanisms are beneficial when cells need to overcome checkpoint activation and recover
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Figure 3. Phospho- and Ubiquitin-
Mediated Regulation of Checkpoint
Kinase 1 (CHK1) Activity and
Stability. (A) CHK1 regulation by ataxia
telangiectasia and Rad3-related protein
kinase (ATR)-dependent phosphorylation
(P) and subsequent automodification,
antagonized by the activities of
the indicated protein phosphatases.
(B) CHK1 regulation by ubiquitylation
(Ub) and proteasomal degradation,
which are antagonized by the activities
of deubiquitinases (DUBs).
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Finally, as opposed to checkpoint termination after resolved replication stress and repaired DNA
damage, checkpoint adaptation as a response to persistent genotoxic stress has been described
[102–104]. As the checkpoint loosens its grip, genomic lesions and incompletely replicated DNA
are transmitted to G2/M for post-replicative repair and for DNA synthesis well beyond S phase.
Such mechanisms, which can enlarge the proliferative capacity of cells under conditions that
challenge genome integrity, and which provide opportunities for cellular evolution and patholog-
ical transformation, challenge the concept of stop and go cell cycle decisions and blur again the
borders between conventionally defined cell cycle phases. Consistently, in cancer cells, segrega-
tion of pervasive, unrepaired lesions into subsequent cell generations shapes the evolution of
cancer genomes and affects their adaptation to chemotherapy [105].
Targeting Replication Checkpoint Kinases for Cancer Therapy
Replication stress and checkpoint signaling can be seen as a continuum, from low and moderate
endogenous replication stress during unperturbed DNA replication to exceedingly high replication
stress levels after oncogene activation, hyperproliferation, or exposure to exogenous agents that
induce severe replication problems and DNA damage. Within this continuum, cancer cells often
show elevated replication stress and are closer to exhausting their replication capacity than
non-cancer cells. Inhibiting ATR–CHK1 signaling, or blocking the related cell cycle kinase and
CDK1 antagonist WEE1 (Box 1), has therefore become a promising avenue in targeted cancer
therapy [54,106]. Several clinical trials have been or are currently testing ATR and CHK1 inhibitors
and putative biomarkers to predict responses to checkpoint kinase inhibition are being evaluated
[107]. Importantly, blocking the kinase activities of ATR, CHK1, or WEE1 synergizes not only with
Checkpoint termination
and adaptation by CHK1 degradation
Intrinsic checkpoint maintenance
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Figure 4. Checkpoint Kinase 1 (CHK1) Stability and Its Links to Checkpoint Activity. (A) Basal CHK1 activity during
normal cell proliferation is needed to maintain CHK1 stability and thereby also maintain intrinsic checkpoint functions. While
CHK1 stability is linked to its autophosphorylation status, basal CHK1 activity is also regulated by SPRTN-dependent removal
of a C-terminal autoinhibitory region. (B) Persistent high levels of CHK1 activation can lead to proteasomal degradation of
CHK1 and its activator Claspin, enabling checkpoint termination or checkpoint adaptation after acute or persistent
genotoxic stress.
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elevated endogenous replication stress in cancer cells, but also with genotoxic stress and DNA
damage induced by orthogonal cancer therapies. For instance, ATR inhibition potentiates the
irradiation-induced type I interferon response [108,109] and checkpoint kinase inhibition
synergizes with dNTP depletion by gemcitabine, which enables the use of significantly lower
drug concentrations, thereby alleviating common side effects such as myelosuppression [107].
Replication stress and replication stress-associated DNA lesions are also caused by poly
(ADP-ribose) polymerase (PARP) inhibition, which is particularly detrimental for BRCA-
deficient cancer cells [107,110]. Acquired PARP inhibitor resistance, a major clinical problem,
can be overcome by inhibition of ATR or CHK1 [111,112]. At least in part, this could be due
to cells entering mitosis prematurely with unresolved PARP inhibitor-induced lesions after inhi-
bition of ATR–CHK1 signaling [110,113]. While this results in cytokinesis failure and mitotic ca-
tastrophe, it also leads to cells that re-enter the cell cycle, albeit with large amounts of genomic
lesions inherited from the previous S phase [110,113]. Such heritable DNA damage, when
allowed to enter the next S phase, will require very tight surveillance by the checkpoint machin-
ery. If the replication checkpoint remains blocked, the likely outcome is excessive damage and
replication catastrophe. If checkpoint inhibition is relieved too early, however, cancer cells
may be able to cope with the extra load of DNA damage and, by reactivating cell cycle brakes
and brake release mechanisms, complete DNA replication and resume proliferation – poten-
tially with newmutations that may render themmore aggressive. As promising as the therapeu-
tic inhibition of replication checkpoint kinases is, in light of their essential functions and our
currently limited understanding of the thresholds that define replication capacity under different
conditions, a cautionary note on the therapeutic window and breadth of applicability seems ex-
pedient. The development of suitable biomarkers and combination therapies has already been
initiated to address such concerns.
Concluding Remarks
While in previous years the focus wasmostly on studying the hammer (i.e., the vigorous activation
of cell cycle checkpoints to halt cell cycle progression in the face of acute and severe threats to
genome stability), more sensitive methods and experimental readouts, including single-cell and
single-molecule analyses, now allow more dedicated studies of the dance of cell cycle control
(Figure 5). In particular, cell cycle-resolved single-cell analyses have the potential to capture the
broad heterogeneity and the dynamics of cellular responses to endogenous replication stress
and to correlate them with cell cycle position and checkpoint activation. The first examples
have revealed that cell cycle boundaries and cell cycle checkpoints can be surprisingly loose,
particularly in transformed cells [105,114]. When viewing the cell cycle as a continuum, with se-
quential yet often unsharp transitions, with a powerful engine fueled by CDK activity that drives
Outstanding Questions
How do multiple sources of ATR and
CHK1 activation cooperate for intrinsic
checkpoint signaling?What are the rel-
ative contributions of the different
coactivators of ATR and CHK1?
Which are, besides their previously
characterized phosphorylation targets,
the critical noncanonical downstream
effectors of ATR and CHK1 activation?
Where in the cell does CHK1
degradation occur and how does it
affect the firing of dormant versus
late replication origins? Can CHK1
degradation occur on chromatin or
is CHK1 release from chromatin a
prerequisite for its degradation? Is the
mechanism of ubiquitin-dependent
CHK1 degradation conserved under
conditions of impaired CHK1 activity
and during checkpoint recovery?
Do the sources of intrinsic checkpoint
activation and the cellular thresholds
that determine brake and brake
release versus full cell cycle arrest
depend on the cell type and the
epigenetic landscape? How does
replication timing influence brake and
brake release mechanisms?
How wide is the therapeutic window
for inhibitors of essential cell cycle
checkpoint kinases in cancer therapy?
How much does it depend on
the cell of origin? Which are the
best biomarkers to predict therapy
responses?
Box 1. The WEE1 Kinase
The WEE1 kinase is a critical component of cell cycle regulation and G2/M checkpoint control. It exerts its function by
restraining CDK activity via inhibitory phosphorylation, which in turn is counteracted by the CDC25A phosphatase. Similar
to ATR and CHK1 inhibition, WEE1 deficiency leads to massive chromosome breakage during DNA replication [115].
WEE1 inhibition promotes unscheduled processing of replication intermediates in S phase, a process that is normally
reserved for mitosis [116]. Additionally, WEE1 inhibition disturbs the temporal segregation between G1 and S phase,
promoting premature S-phase entry and dormant origin firing [117]. Like ATR and CHK1, the WEE1 kinase is a promising
target in cancer therapy, and WEE1 inhibition was recently shown to synergize with CHK1 inhibition in causing unsched-
uled origin firing and DNA damage in S phase [118]. Through untimely CDK activation, WEE1 inhibition also leads to
degradation of the RNR subunit RRM2, thereby causing a shortage in dNTP supply. This is particularly important in
H3K36me3-deficient cancers, where WEE1 inhibition-induced RRM2 destabilization synergizes with impaired RRM2
transcription to cause excessive replication stress and cell death [119]. WEE1 inhibition may also be beneficial in
conjunction with other genotoxic drugs such as PARP inhibitors, when applied either in combination or sequentially to
reduce toxicity [120].
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cell cycle progression forward and with tunable brakes and brake release mechanisms that dy-
namically control the ride, delaying certain tasks for the benefit of others and thereby ignoring
conventionally defined cell cycle boundaries might simply be a way to balance resources and
pay tribute to time being limited for cell cycle completion. Consistently, the replication checkpoint
is likely to comprise various degrees of gradually tunable signaling strength, rather than resting ei-
ther in an off or in an on state, and cells thus progress through S phase always with ‘one foot on
the brake’. However, several important points still need to be addressed in more detail; for
instance, with regard to the sources of intrinsic checkpoint activation and the cellular thresholds
of brake and brake release mechanisms (see Outstanding Questions). Only once a more
quantitative, systematic, and comprehensive understanding is obtained, are targeted therapies
using checkpoint kinase inhibitors, as standalone agents or in combination therapies, bound to
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Figure 5. The Hammer and the Dance of Cell Cycle Regulation. In response to severe threats to genome integrity,
when the capacity of the DNA replication and repair systems is in danger of becoming exhausted, strong cell cycle
checkpoint activation can be seen as the hammer, which forcefully limits further damage and thereby helps to contain the
distress. For instance, global inhibition of new origin firing by deoxyribonucleotide triphosphate (dNTP) depletion or
slowdown of replicative polymerases prevents the formation of excessive amounts of unwound single-stranded DNA
(ssDNA), at the cost of temporarily pausing the process of genome duplication. Such a stop decision, triggered by full
ataxia telangiectasia and Rad3-related protein kinase (ATR) and checkpoint kinase 1 (CHK1) activation, is required to
ensure that the replication capacity, including the capacity of fork protection mechanisms, is not exhausted and to thereby
prevent catastrophic genome damage. When conditions are back under control, the capacity of the system is sufficiently
large to cope with naturally occurring replication stress and spontaneously occurring DNA lesions in a more flexible
manner, using brake and brake release mechanisms with fine-tuned regulation of the ATR and CHK1 checkpoint kinases
and of cell cycle-driving cyclin–CDK activities. In keeping with ‘the hammer and the dance’ metaphor, normal cells take
risks with genome-compromising potential seriously and exert tight control to minimize the damage, whereas cancer cells
often ignore the risks and act sloppily in their response. Note that while in principle the hammer may be required at any
time during S-phase progression to prevent exhaustion of the replication capacity, and may be preceded by a dance
phase, the passive replication of excess origins during the course of genome duplication gradually lowers the risk of origin
firing-associated DNA damage in both normal and cancer cells.
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